Reaction
Oral Mucosal Eruption reporting signals
As of the last recalculation, Oral Mucosal Eruption appears in 1,510 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is ACETYLCYSTEINE (PRR 20.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Acetylcysteine | 14 | 20.7 | 20.7 |
| Alpelisib | 11 | 17.5 | 17.5 |
| Bimekizumab | 18 | 11.8 | 11.8 |
| Umeclidinium | 7 | 10.8 | 10.8 |
| Nicotine Polacrilex | 28 | 10.3 | 10.3 |
| Isosorbide Dinitrate | 14 | 10.0 | 10.0 |
| Mesna Injection | 5 | 8.4 | 8.4 |
| Mesna | 5 | 8.2 | 8.2 |
| Panitumumab | 8 | 7.1 | 7.1 |
| Cabozantinib | 23 | 6.7 | 6.7 |
| Rocuronium Bromide | 5 | 5.9 | 5.9 |
| Erlotinib | 4 | 5.7 | 5.7 |
| Fluticasone Propionate And Salmeterol | 17 | 5.7 | 5.7 |
| Sunitinib Malate | 16 | 5.7 | 5.7 |
| Mometasone Furoate And Formoterol Fumarate Dihydrate | 6 | 5.3 | 5.3 |
| Buprenorphine Hydrochloride, Naloxone Hydrochloride | 9 | 5.2 | 5.2 |
| Inclisiran | 3 | 5.2 | 5.2 |
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 14 | 4.7 | 4.7 |
| Axitinib | 6 | 4.3 | 4.3 |
| Nemolizumab-Ilto | 3 | 3.3 | 3.3 |
| Nirmatrelvir And Ritonavir | 8 | 2.0 | 2.0 |
| Dupilumab | 64 | 1.9 | 1.9 |